German pharma giant teams up with China's top university

German pharmaceutical giant Boehringer Ingelheim and Tsinghua University set up a joint scientific hub for the R&D of immunological therapies for infectious diseases.

Clive Wood, Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim (front right) and professor Dong Chen, Dean of School of Medicine at the Tsinghua University(left), signing the collaboration deal in Beijing over the weekend. 

German pharmaceutical giant Boehringer Ingelheim and Tsinghua University said they have launched a joint scientific hub for the research and development of immunological therapies for infectious diseases.

The Boehringer Ingelheim-Tsinghua University Joint Research Center for Immuno-Infection aims to harness the mechanisms of immune modulation to combat infectious diseases, according to a joint announcement over the weekend.

“For Tsinghua University, innovation is one of the most important aspects we pursue, and this is the basis and synergy for this partnership,” Professor You Zheng, vice president of Tsinghua University said.

“The joint scientific hub gives our scientists the opportunity to work hand in hand with outstanding scientists from Tsinghua University to discover novel treatment approaches in the field of immunology and infectious diseases,” added Clive Wood, senior corporate vice president of Discovery Research at Boehringer Ingelheim.

“This partnership has the potential to open new approaches for currently untreatable infectious diseases,” he noted. 

The collaboration aims to bring the leading expertise of Tsinghua University in infectious disease research and immunology together with Boehringer Ingelheim’s experience in its comprehensive research and development programs in cancer immunology and immune modulation. 

“Our collaboration with Tsinghua University is a further expression of our strong commitment to supporting research and development in China, and acknowledges the leading position China has achieved in many scientific areas,” David Preston, President and CEO of Boehringer Ingelheim China said.


Special Reports
Top